Skip to main content

Phagos

Category: AI in Biotech / Drug Discovery

AI-powered phage therapies to combat antibiotic resistance in animals. Phagos was founded in 2021. The company is led by Alexandros Pantalis. Based in Paris, France. Team size: 11-50. Total funding raised: €27.4 million. Latest round: Series A, €25.0M, 2025-10, led by CapAgro, Hoxton Ventures, CapHorn, and Demeter. Key investors include ["CapAgro","Hoxton Ventures","CapHorn","Demeter","Acurio Ventures","Citizen Capital","Entrepreneur First","Founders Capital","Station F"].

Founded
2021
Headquarters
Paris, France
Team size
11-50
Total funding
€27.4 million

Value proposition

Provides a rapid (2-month development cycle) and sustainable alternative to antibiotics, offering personalized treatments against resistant bacteria.

Products and solutions

["Custom bacteriophage solutions","AI-driven phage discovery platform"]

Unique value

The use of a proprietary AI platform to analyze a vast library of bacteriophages and rapidly develop highly targeted treatments against specific bacterial infections.

Target customer

Veterinary and aquaculture sectors, specifically chicken, cattle, swine, and shrimp farms.

Industries served

["Animal Health","Veterinary","Aquaculture"]

Technology advantage

Their AI-powered platform significantly accelerates the discovery and development of personalized phage therapies, enabling a much faster response to emerging bacterial threats compared to traditional methods.

How they differentiate

Phagos differentiates itself by using a proprietary AI platform to develop personalized phage therapies that serve as a sustainable alternative to antibiotics in animal health. This AI-driven approach allows them to create targeted treatments for bacterial diseases in just two months.

Main competitors

["MaaT Pharma","Mikrobiomik","Spero Therapeutics"]

Key partnerships

["Amazon Web Services (AWS)"]

Notable customers

["While specific names are not public, Phagos targets chicken, cattle, swine, and shrimp farms."]

Major milestones

["Secured €25 million in a Series A funding round.","Developed a unique AI model on Amazon Web Services (AWS) to overcome antibiotic resistance.","Successfully raised a €2.4 million seed round in 2022."]

Growth metrics

Specific growth metrics are not publicly available.

Market positioning

Phagos is positioned as a biotechnology company at the intersection of AI and phage therapy, focusing on the veterinary market. They aim to combat antibiotic resistance in animal agriculture by providing a rapid, personalized, and sustainable solution.

Geographic focus

While Phagos is based in Paris, France, their focus is global. They serve chicken, cattle, swine, and shrimp farms worldwide, with the recent funding intended to accelerate their global expansion.

Patents and IP

The company has a patented AI technology for phage discovery.

About Alexandros Pantalis

Co-founder and CEO of Phagos. Previously involved with Entrepreneur First, a company builder and early-stage investor. His background is in economics, and he transitioned into the biotech space to address the challenge of antibiotic resistance.

Official website: